Portugal has a strong and growing health sector, with internationally recognized companies producing high-quality healthcare products and services. Exports from the Portuguese health sector grew 123% between 2008-2017. The country also has a vibrant research and development ecosystem in life and health sciences, with scientific production growing 89% between 2008-2015. Portugal's high-quality education and healthcare systems further support the strong health sector. Given its strengths, Portugal is well-positioned to partner with companies on research, clinical trials, and production.
The document provides an overview of the life sciences and healthcare sector in Catalonia's "BioRegion". It summarizes that the sector contributes 7.3% to Catalonia's GDP and includes over 1,200 companies, mainly in biotech, pharma, medtech, and digital health. Investment in startups has grown steadily over the past five years to a record €120 million in 2020. The BioRegion has strong science and technology assets, including research centers, universities, and large infrastructures conducting cutting-edge research. Future challenges include improving technology transfer, attracting and developing talent, increasing investment, and ensuring a sustainable public health system.
Biocat has experience in accelerating healthcare projects and developing talent since 2008. In 10 years, Biocat has invested over €11 million, distributed in 300 programs attended by more than 2,300 students. By leveraging its expert, industry experienced, staff and extended network, Biocat has successfully accelerated 96 life sciences projects that generated 300 new job positions, increased the rate of successful commercialization and reduced the time to next phase. In 2013, in order to increase the impact of these strategic activities. Biocat launched Moebio, a new initiative that brings together diferent training programs to accelerate entrepreneurship and innovation in healthcare, that counts with the support of EIT Health. Moebio is ranked as one of the top accelerators in Europe according to rankings by Digitalhealth.careers, Mobile World Capital, Tech EU and HealthStartup.
Design Health Barcelona (d·HEALTH Barcelona) is a 9-month postgraduate program to develop entrepreneurs and future leaders in healthcare innovation. The course, based on the prestigious Stanford University's Biodesign Fellowship, has a needs-driven innovation focus and it guides multidisciplinary groups of students through a full cycle of innovation, from needs identification to designing and prototyping a viable solution, as well as searching for funding.
www.moebio.org
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14Aurore Beaume
The document summarizes a report on the health care biotechnology industry in France. It finds that the sector has grown since 2010 and now includes 457 companies, mainly micro-enterprises. The companies focus on oncology and infectious diseases. While public-private collaborations are common, private funding is lacking, especially for company development beyond the startup stage. The report identifies areas for improvement such as increasing private financing, supporting company growth, strengthening collaborations, and enhancing an international mindset.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
http://pwc.to/1bAPmr1
L'étude « Socio-economic impact of mHealth » est une étude prospective réalisée par PwC, qui s'appuie sur une quantité importante de données permettant d'analyser l'impact économique de la m-Santé dans les 27 pays de l'Union européenne.
The document summarizes key information about Austria as a location for life sciences industries including pharmaceuticals, biotechnology, and medical engineering. Some of the main points covered include:
- Austria has a strong network of over 720 life sciences companies that employ 50,000 people and generate 5.4% of GDP.
- Vienna is a major hub for biotechnology research and home to half of Austria's biotech firms. Cancer research and medical engineering are also areas of focus.
- The country offers attractive tax incentives for research and development including a 12% research premium and tax advantages.
- Austria has a dense network of over 50 competence centers that link scientific and industrial communities to drive innovation, such as Oncotyrol
Value-based healthcare in Germany: From free price-setting to a regulated market is a report by The Economist Intelligence Unit (EIU), commissioned by Gilead Sciences. It looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
The document provides an overview of the life sciences and healthcare sector in Catalonia's "BioRegion". It summarizes that the sector contributes 7.3% to Catalonia's GDP and includes over 1,200 companies, mainly in biotech, pharma, medtech, and digital health. Investment in startups has grown steadily over the past five years to a record €120 million in 2020. The BioRegion has strong science and technology assets, including research centers, universities, and large infrastructures conducting cutting-edge research. Future challenges include improving technology transfer, attracting and developing talent, increasing investment, and ensuring a sustainable public health system.
Biocat has experience in accelerating healthcare projects and developing talent since 2008. In 10 years, Biocat has invested over €11 million, distributed in 300 programs attended by more than 2,300 students. By leveraging its expert, industry experienced, staff and extended network, Biocat has successfully accelerated 96 life sciences projects that generated 300 new job positions, increased the rate of successful commercialization and reduced the time to next phase. In 2013, in order to increase the impact of these strategic activities. Biocat launched Moebio, a new initiative that brings together diferent training programs to accelerate entrepreneurship and innovation in healthcare, that counts with the support of EIT Health. Moebio is ranked as one of the top accelerators in Europe according to rankings by Digitalhealth.careers, Mobile World Capital, Tech EU and HealthStartup.
Design Health Barcelona (d·HEALTH Barcelona) is a 9-month postgraduate program to develop entrepreneurs and future leaders in healthcare innovation. The course, based on the prestigious Stanford University's Biodesign Fellowship, has a needs-driven innovation focus and it guides multidisciplinary groups of students through a full cycle of innovation, from needs identification to designing and prototyping a viable solution, as well as searching for funding.
www.moebio.org
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14Aurore Beaume
The document summarizes a report on the health care biotechnology industry in France. It finds that the sector has grown since 2010 and now includes 457 companies, mainly micro-enterprises. The companies focus on oncology and infectious diseases. While public-private collaborations are common, private funding is lacking, especially for company development beyond the startup stage. The report identifies areas for improvement such as increasing private financing, supporting company growth, strengthening collaborations, and enhancing an international mindset.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
http://pwc.to/1bAPmr1
L'étude « Socio-economic impact of mHealth » est une étude prospective réalisée par PwC, qui s'appuie sur une quantité importante de données permettant d'analyser l'impact économique de la m-Santé dans les 27 pays de l'Union européenne.
The document summarizes key information about Austria as a location for life sciences industries including pharmaceuticals, biotechnology, and medical engineering. Some of the main points covered include:
- Austria has a strong network of over 720 life sciences companies that employ 50,000 people and generate 5.4% of GDP.
- Vienna is a major hub for biotechnology research and home to half of Austria's biotech firms. Cancer research and medical engineering are also areas of focus.
- The country offers attractive tax incentives for research and development including a 12% research premium and tax advantages.
- Austria has a dense network of over 50 competence centers that link scientific and industrial communities to drive innovation, such as Oncotyrol
Value-based healthcare in Germany: From free price-setting to a regulated market is a report by The Economist Intelligence Unit (EIU), commissioned by Gilead Sciences. It looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
This document provides an overview of the biomanufacturing sector in Germany. It details that Germany leads Europe in fermentation capacity for biopharmaceutical production. The medical biotechnology sector is a strong focus, particularly for production of antibodies, vaccines, and cancer treatments. The directory section lists several German companies that offer microbial and mammalian cell-based expression systems and contract manufacturing services up to phase 3 clinical trials. Key companies profiled include BIBITEC, BIOMEVA, and IDT Biologika.
This document provides an introduction and agenda for a workshop on the Norwegian healthcare market. The workshop aims to give participants an overview of the Norwegian healthcare system and regions, discuss needs and offerings, and allow questions. The agenda includes introductions, a discussion of strategic priorities and needs in Norway, differences from Finland, procurement policies, a group exercise matching offers to needs, and a Q&A. Key priorities in Norway include improving quality and access, digital transformation, and reducing costs while meeting increased demand. An upcoming reform aims to create larger, more capable municipalities to better deliver services.
1. The document discusses investments for early stage companies from ZJ Venture, a venture capital firm located in Zhangjiang Hi-Tech Park in Shanghai, China.
2. It provides an overview of the various industries and sectors represented in Zhangjiang Hi-Tech Park, including information technology, biotechnology, clean technology, and others.
3. ZJ Venture has invested a total of 1.88 billion RMB across 41 different companies, focusing on sectors like ICT, energy technology, and biotechnology. It also discusses establishing joint funds with partners to invest in early stage companies.
The document summarizes key points from an annual meeting of the Irish Pharmaceutical Healthcare Association. It notes that foreign direct investment has had a major economic impact in Ireland, contributing over €110 billion in exports and creating 240,000 jobs. It highlights Ireland's leadership in attracting investments from top companies in pharmaceuticals, medical devices, ICT and financial services. The document then outlines sectors of focus for the IDA and recent foreign direct investment wins. It discusses trends and challenges in the pharmaceutical and medical technologies industries. Finally, it outlines Ireland's initiatives to support the continued growth of the life sciences sector.
1. The European Parliament formally opposed cuts to Horizon 2020 funding and wants to protect the research program's budget.
2. A seminar on business and research called for continued investment in medical R&D and patient access to new therapies while maintaining sustainable healthcare budgets.
3. A Commission working group on disruptive health innovation agreed to use the term "High Value Innovation" instead of "Disruptive Innovation" and will further develop the definition and taxonomy.
4. Negotiations on the Transatlantic Trade and Investment Partnership (TTIP) between the EU and US are ongoing, with discussions around mutual recognition of quality standards for medical devices, but some European parliamentary committees want certain health areas excluded from the
Bosch Packaging Technology - what influences pharmaceutical industry today an...workpat123
The document discusses trends influencing the pharmaceutical industry today and tomorrow. It identifies key trends such as increasing demand for personalized medicines, price pressures, and higher quality standards. It also discusses how new technologies like continuous manufacturing, isolators, Industry 4.0 solutions, and partnerships can help pharmaceutical companies address these trends. Bosch Packaging Technology provides technologies and services across the product lifecycle to support pharmaceutical customers in meeting new demands and regulatory requirements.
Following North America and EU, Southeast and East Asia is ranked 3rd the highest projected pharmaceutical sales in 2024 with the value of USD 232 billion. As part of the region, Thailand’s pharmaceutical industry has grown and has been considered one of the top biopharma clusters regarding its public R&D spending, number of patents, initial public offerings, number of companies, and jobs.
The document discusses opportunities for Northern Ireland in the fields of personalized medicine and home-based care. It outlines how personalized medicine could transform healthcare by tailoring treatment to individual genetics and biomarkers, bringing benefits to patients, industry, and governments. The personalized medicine market is estimated to exceed $250 billion if it accounts for 25% of pharmaceutical sales. The document proposes that Northern Ireland become a center for integrated research and development in personalized medicine to develop local businesses and attract investment. It also discusses how home-based care technologies can help manage chronic diseases and extend independent living for seniors by remotely monitoring health data. The home care market is rapidly growing and presents opportunities for Northern Ireland to adopt telehealth systems and become an attractive test bed for international technology
The document discusses why London is an attractive location for life sciences businesses, highlighting its large life sciences sector, world-class universities and research institutions, supportive government policies and funding, strong talent pool, and collaborative environment including incubators, research centers like the Francis Crick Institute and Cell Therapy Catapult, and institutions supporting clinical trials and commercialization. London has over 1,000 life sciences companies and is a leader in areas like pharmaceuticals, biotechnology, and medical technology.
mHealth Israel_Rhon klinikum overview_Oct 2015_Digital Health and Network Med...Levi Shapiro
This document provides an overview of RHÖN-KLINIKUM AG's strategy for digital health and network medicine. It discusses how digitalization is transforming healthcare systems towards more efficient and patient-centered care. RHÖN-KLINIKUM plans to invest in innovative digital health startups and develop an "Alliance Platform" to facilitate network medicine between hospitals, doctors, and other providers. The platform will use technologies like master patient indexing to securely share patient data across organizations and support coordinated care through the continuum.
The BioRegion Report is the benchmark study on the life sciences and healthcare ecosystem in Catalonia. It highlights the main macroeconomic data on the sector, including updated investment figures.
The document provides an overview of the life sciences and healthcare sector in Catalonia in 2021. It summarizes that 2021 saw significant growth and investment in healthcare innovation globally and in Catalonia. The sector accounts for 8.7% of Catalonia's GDP and employs over 244,000 people. Key indicators like turnover, employment, and investment continued to increase in 2021 despite the pandemic. The ecosystem includes over 1,300 companies, primarily in biotech, pharma, medtech, and digital health, as well as 91 research institutions.
The BioRegion Report is the benchmark study on the life sciences and healthcare ecosystem in Catalonia. It highlights the main macroeconomic data on the sector, including updated investment figures.
Portugal Dental Care Market Analysis Sample ReportInsights10
Portugal's Dental Care Market is at around $107.6 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Independently recovered from country debts is now a major tourism hotspot with attractions like vast coastline and heritage sites, it is now venturing into dental tourism, made easy with insurance coverage by companies like Cigna Global. To get a detailed report, contact us at - info@insights10.com
Here are the key points about the VAALID project:
- It aims to develop new tools and methods to facilitate and improve the design, development, testing and evaluation processes for ambient assisted living (AAL) technology solutions.
- The goal is to ensure the accessibility and usability of AAL environments for elderly users.
- It focuses on professionals involved in the design and evaluation of human-machine interaction for AAL solutions.
- The main outcome is an Integrated Development Environment (IDE) platform with tools to support the computer-assisted design, simulation and validation of user interaction components.
- The IDE has a Creation Environment for virtually constructing interactive elements, and a Simulation Environment for users to experience design alternatives
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
GCF - Présentation Medical & Health - 1222.pdfHlnePEYRUSQUE
The document discusses trends in the medical and health sector including market growth, popular investment areas, and the impact of digitalization. It notes that M&A deals in pharma make up the largest deal value and volume, and that consolidation is occurring in the private health services sector. Valuation metrics vary based on company size, profitability, and market position. The author's firm provides M&A advisory services and fundraising for medical and health companies, with expertise across Europe, Asia, and other regions. It utilizes tailored processes for buy-side mandates, sell-side mandates, and fundraising.
GCF - Présentation Medical & Health - 1022.pdfLucas518833
- Negotiation of the Letter of Intent
- Negotiation of the Share Purchase
Agreement
- Closing of the transaction
- Post-closing support
Option: Preparation of a 'Long-List' of
potential targets in the targeted sector
and geographical area and ranking them
in order of interest and according to M&A
criteria (sales, EBITDA, etc.)
Initiate contact between GEREJE and the
target(s) (without giving the name of the
client) to validate their actionability
Meeting between GEREJE and the client
to select a short list of targets to be
approached in phase 2
Assist our client in the final Due
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
1. The document discusses a speech given by a French Minister to an international pharmaceutical research group about France's efforts to combat infectious diseases through increased medical research funding and public-private partnerships.
2. Over the past 4 years, France has massively increased funding for medical research and provided tax incentives to encourage partnerships between public research laboratories and private companies.
3. Key initiatives include the creation of a research alliance called AVIESAN to better coordinate resources and projects, as well as programs that provide over €1 billion in funding for projects related to biomedical research and technologies.
Switzerland has a strong pharmaceutical industry that makes up about a third of its exports and contributes substantially to the national economy. It has a highly educated workforce and world-class research institutions that support innovation. Major companies like Roche and Novartis invest billions annually in R&D. Switzerland ranks first globally in measures of innovation and files more pharmaceutical patents per capita than other countries. Its business-friendly policies and skilled labor force make it an attractive location for pharmaceutical and biotech companies.
This document provides an overview of the biomanufacturing sector in Germany. It details that Germany leads Europe in fermentation capacity for biopharmaceutical production. The medical biotechnology sector is a strong focus, particularly for production of antibodies, vaccines, and cancer treatments. The directory section lists several German companies that offer microbial and mammalian cell-based expression systems and contract manufacturing services up to phase 3 clinical trials. Key companies profiled include BIBITEC, BIOMEVA, and IDT Biologika.
This document provides an introduction and agenda for a workshop on the Norwegian healthcare market. The workshop aims to give participants an overview of the Norwegian healthcare system and regions, discuss needs and offerings, and allow questions. The agenda includes introductions, a discussion of strategic priorities and needs in Norway, differences from Finland, procurement policies, a group exercise matching offers to needs, and a Q&A. Key priorities in Norway include improving quality and access, digital transformation, and reducing costs while meeting increased demand. An upcoming reform aims to create larger, more capable municipalities to better deliver services.
1. The document discusses investments for early stage companies from ZJ Venture, a venture capital firm located in Zhangjiang Hi-Tech Park in Shanghai, China.
2. It provides an overview of the various industries and sectors represented in Zhangjiang Hi-Tech Park, including information technology, biotechnology, clean technology, and others.
3. ZJ Venture has invested a total of 1.88 billion RMB across 41 different companies, focusing on sectors like ICT, energy technology, and biotechnology. It also discusses establishing joint funds with partners to invest in early stage companies.
The document summarizes key points from an annual meeting of the Irish Pharmaceutical Healthcare Association. It notes that foreign direct investment has had a major economic impact in Ireland, contributing over €110 billion in exports and creating 240,000 jobs. It highlights Ireland's leadership in attracting investments from top companies in pharmaceuticals, medical devices, ICT and financial services. The document then outlines sectors of focus for the IDA and recent foreign direct investment wins. It discusses trends and challenges in the pharmaceutical and medical technologies industries. Finally, it outlines Ireland's initiatives to support the continued growth of the life sciences sector.
1. The European Parliament formally opposed cuts to Horizon 2020 funding and wants to protect the research program's budget.
2. A seminar on business and research called for continued investment in medical R&D and patient access to new therapies while maintaining sustainable healthcare budgets.
3. A Commission working group on disruptive health innovation agreed to use the term "High Value Innovation" instead of "Disruptive Innovation" and will further develop the definition and taxonomy.
4. Negotiations on the Transatlantic Trade and Investment Partnership (TTIP) between the EU and US are ongoing, with discussions around mutual recognition of quality standards for medical devices, but some European parliamentary committees want certain health areas excluded from the
Bosch Packaging Technology - what influences pharmaceutical industry today an...workpat123
The document discusses trends influencing the pharmaceutical industry today and tomorrow. It identifies key trends such as increasing demand for personalized medicines, price pressures, and higher quality standards. It also discusses how new technologies like continuous manufacturing, isolators, Industry 4.0 solutions, and partnerships can help pharmaceutical companies address these trends. Bosch Packaging Technology provides technologies and services across the product lifecycle to support pharmaceutical customers in meeting new demands and regulatory requirements.
Following North America and EU, Southeast and East Asia is ranked 3rd the highest projected pharmaceutical sales in 2024 with the value of USD 232 billion. As part of the region, Thailand’s pharmaceutical industry has grown and has been considered one of the top biopharma clusters regarding its public R&D spending, number of patents, initial public offerings, number of companies, and jobs.
The document discusses opportunities for Northern Ireland in the fields of personalized medicine and home-based care. It outlines how personalized medicine could transform healthcare by tailoring treatment to individual genetics and biomarkers, bringing benefits to patients, industry, and governments. The personalized medicine market is estimated to exceed $250 billion if it accounts for 25% of pharmaceutical sales. The document proposes that Northern Ireland become a center for integrated research and development in personalized medicine to develop local businesses and attract investment. It also discusses how home-based care technologies can help manage chronic diseases and extend independent living for seniors by remotely monitoring health data. The home care market is rapidly growing and presents opportunities for Northern Ireland to adopt telehealth systems and become an attractive test bed for international technology
The document discusses why London is an attractive location for life sciences businesses, highlighting its large life sciences sector, world-class universities and research institutions, supportive government policies and funding, strong talent pool, and collaborative environment including incubators, research centers like the Francis Crick Institute and Cell Therapy Catapult, and institutions supporting clinical trials and commercialization. London has over 1,000 life sciences companies and is a leader in areas like pharmaceuticals, biotechnology, and medical technology.
mHealth Israel_Rhon klinikum overview_Oct 2015_Digital Health and Network Med...Levi Shapiro
This document provides an overview of RHÖN-KLINIKUM AG's strategy for digital health and network medicine. It discusses how digitalization is transforming healthcare systems towards more efficient and patient-centered care. RHÖN-KLINIKUM plans to invest in innovative digital health startups and develop an "Alliance Platform" to facilitate network medicine between hospitals, doctors, and other providers. The platform will use technologies like master patient indexing to securely share patient data across organizations and support coordinated care through the continuum.
The BioRegion Report is the benchmark study on the life sciences and healthcare ecosystem in Catalonia. It highlights the main macroeconomic data on the sector, including updated investment figures.
The document provides an overview of the life sciences and healthcare sector in Catalonia in 2021. It summarizes that 2021 saw significant growth and investment in healthcare innovation globally and in Catalonia. The sector accounts for 8.7% of Catalonia's GDP and employs over 244,000 people. Key indicators like turnover, employment, and investment continued to increase in 2021 despite the pandemic. The ecosystem includes over 1,300 companies, primarily in biotech, pharma, medtech, and digital health, as well as 91 research institutions.
The BioRegion Report is the benchmark study on the life sciences and healthcare ecosystem in Catalonia. It highlights the main macroeconomic data on the sector, including updated investment figures.
Portugal Dental Care Market Analysis Sample ReportInsights10
Portugal's Dental Care Market is at around $107.6 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Independently recovered from country debts is now a major tourism hotspot with attractions like vast coastline and heritage sites, it is now venturing into dental tourism, made easy with insurance coverage by companies like Cigna Global. To get a detailed report, contact us at - info@insights10.com
Here are the key points about the VAALID project:
- It aims to develop new tools and methods to facilitate and improve the design, development, testing and evaluation processes for ambient assisted living (AAL) technology solutions.
- The goal is to ensure the accessibility and usability of AAL environments for elderly users.
- It focuses on professionals involved in the design and evaluation of human-machine interaction for AAL solutions.
- The main outcome is an Integrated Development Environment (IDE) platform with tools to support the computer-assisted design, simulation and validation of user interaction components.
- The IDE has a Creation Environment for virtually constructing interactive elements, and a Simulation Environment for users to experience design alternatives
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
GCF - Présentation Medical & Health - 1222.pdfHlnePEYRUSQUE
The document discusses trends in the medical and health sector including market growth, popular investment areas, and the impact of digitalization. It notes that M&A deals in pharma make up the largest deal value and volume, and that consolidation is occurring in the private health services sector. Valuation metrics vary based on company size, profitability, and market position. The author's firm provides M&A advisory services and fundraising for medical and health companies, with expertise across Europe, Asia, and other regions. It utilizes tailored processes for buy-side mandates, sell-side mandates, and fundraising.
GCF - Présentation Medical & Health - 1022.pdfLucas518833
- Negotiation of the Letter of Intent
- Negotiation of the Share Purchase
Agreement
- Closing of the transaction
- Post-closing support
Option: Preparation of a 'Long-List' of
potential targets in the targeted sector
and geographical area and ranking them
in order of interest and according to M&A
criteria (sales, EBITDA, etc.)
Initiate contact between GEREJE and the
target(s) (without giving the name of the
client) to validate their actionability
Meeting between GEREJE and the client
to select a short list of targets to be
approached in phase 2
Assist our client in the final Due
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
1. The document discusses a speech given by a French Minister to an international pharmaceutical research group about France's efforts to combat infectious diseases through increased medical research funding and public-private partnerships.
2. Over the past 4 years, France has massively increased funding for medical research and provided tax incentives to encourage partnerships between public research laboratories and private companies.
3. Key initiatives include the creation of a research alliance called AVIESAN to better coordinate resources and projects, as well as programs that provide over €1 billion in funding for projects related to biomedical research and technologies.
Switzerland has a strong pharmaceutical industry that makes up about a third of its exports and contributes substantially to the national economy. It has a highly educated workforce and world-class research institutions that support innovation. Major companies like Roche and Novartis invest billions annually in R&D. Switzerland ranks first globally in measures of innovation and files more pharmaceutical patents per capita than other countries. Its business-friendly policies and skilled labor force make it an attractive location for pharmaceutical and biotech companies.
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Healthcare, from Products to Solutions Exploring some of the latest initiativ...Alix Aubert
with high-level healthcare executives. Today, through Life Science Talks, we have decided to make some of this information available
to the professional community at large, provided it is non-confidential, of public interest, and likely to spark interesting partnerships in
the future.
This white paper therefore condenses data drawn from a number of informative meetings with decision makers in the European
healthcare sector during 2013 and 2014. More specifically, it is the result of an edition of Life science Talks dedicated to this subject
and held in Paris, in May 2014.
The discussions at this event were admirably moderated by Silvia Ondategui Parra, partner at EY, and were punctuated by keynotes
from leading stakeholders in European healthcare: Emmanuel Gomez, CNAM-TS, Head of Disease Management Programmes; Dr Rick
Greville, ABPI, Director of Wales and International Affairs; Thierry Zylberberg, Orange, Head of Orange Healthcare; Miguel Bernabeu,
Alcon (Novartis), Global Head of Market Access, Pricing and HEOR; Yvoine McCourt, Air Liquide, Head of Home Healthcare
International Development; Olivier Croly, GE Healthcare IT, GM Europe. Again, we thank them for sharing their views, their concerns,
and for outlining their projects in Europe within our forum.
V3 chester women´s network ukti bcn march 2014ellisandco
Check out our presentation about how to trade your goods in Spain, shown at the Chester Women's Network hosted by Ellis & Co Chartered Accountants and Business Advisers in Chester.
GCF - Our added value in Medical & Health sector 0923 .pdfHannahDerenbach
This document provides an overview of trends in the medical and health sector as well as Gereje Corporate Finance's expertise in advising clients in this industry. It discusses the strong growth of the global medical market driven by aging populations, increasing healthcare costs, and digitalization. M&A activity is also increasing with deals focused on pharmaceutical consolidation, private clinic mergers, and growing private equity interest. Gereje's services include identifying acquisition targets, optimizing negotiations, fundraising, and structuring deals for both buyers and sellers in the medical space.
GCF - Our added value in Medical & Health sector 0923 .pdfsunclarisse
This document provides an overview of trends in the medical and health sector as well as Gereje Corporate Finance's expertise in advising clients in this industry. It discusses the strong growth of the global medical market driven by aging populations, increasing healthcare costs, and digitalization. M&A activity is also increasing with deals focused on pharmaceutical consolidation, private clinic mergers, and growing private equity interest. Gereje's services include identifying acquisition targets, optimizing negotiations, fundraising, and structuring deals for both buyers and sellers in the medical space.
GCF - Our added value in Medical & Health sector - 0823 .pdfHannahDerenbach
The document discusses trends in the medical and healthcare M&A market. It notes growing M&A activity driven by an aging population, increasing healthcare costs, and digitalization. Major trends include consolidation in pharmaceuticals and private healthcare as well as growing appetite from investment funds. Valuation multiples vary based on factors like company size, profitability, and market position. The document also outlines GEREJE Corporate Finance's expertise in M&A advisory for the healthcare sector, including their network of companies and investors as well as methodology for buy-side M&A transactions.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
Biocat is the institution that brings together the life sciences and healthcare innovation community in Catalonia.
Created in 2006 at the behest of the Government of Catalonia, Biocat’s mission is to maximize the economic and social impact of the life sciences and healthcare innovation of the BioRegion.
Biocat focuses its strategy on different key points:
- Raising awareness and promoting the ecosystem, creating tools and strategies for improving the knowledge of the Catalan healthcare sector and increasing its projection both at home and abroad, with the aim of positioning the BioRegion as an international reference.
- Providing innovative training and developing talent, by designing and executing programs and initiatives to improve talent and entrepreneurship considered essential factors for the growth of the sector.
- Accelerating technology transfer and business growth by supporting and carrying out activities for increasing the value of the sector, placing special emphasis on the added value of research, knowledge and technology transfer, internationalization and access to capital.
Similar to Portugal: the right place to invest and build partnerships in Health | Health Cluster Portugal [January 2019] (20)
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Portugal: the right place to invest and build partnerships in Health | Health Cluster Portugal [January 2019]
1. 1/8HCP | January 2019 | www.healthportugal.com
PORTUGAL: THE RIGHT PLACE TO INVEST AND BUILD PARTNERSHIPS IN HEALTH
The Health sector is a prominent, fast-evolving sector in Portugal, which has
experienced a remarkable evolution during the last couple of decades.
‘Made in Portugal’ means quality, reliability and competitiveness. Portuguese companies
are internationally recognised as high-quality suppliers of healthcare products and services
– e.g., pharmaceuticals, medical devices and other medical technologies –, having high standards
of quality and being capable of developing, manufacturing and supplying a wide range of solutions,
with high flexibility. A consistent offer also exists in the country in terms of contract development
and manufacturing organisations, and producers of active pharmaceutical ingredients.
The Portuguese pharmaceutical and medical device industries have grown above the country’s
average in recent years, with increasing exports to countries such as the USA, Germany, UK, Spain
and France. The Portuguese exports of goods from the health sector have grown by 123%
between 2008 and 2017, to a value of EUR 1,398 million. This includes the export of
pharmaceutical preparations (1,002 million), basic pharmaceutical products (93 million), medical
and dental instruments and supplies (289 million), and irradiation, electromedical and
electrotherapeutic equipment (14 million), not including sales of eHealth solutions and services.
Portugal has a vibrant and innovative Research & Development ecosystem, characterized by
the presence of world-class institutions and scientists – international panels of experts have
classified 13 out of 24 Portuguese Life and Health Sciences R&D Units as Exceptional, Excellent
or Very Good. The Portuguese scientific production in the areas of medical and health
sciences (includes clinical medicine, basic medicine, and health sciences), life sciences and
medical engineering has grown by 89% between 2008 and 2015, to a value of 8,096
publications – 38% of the entire scientific production of the country.
On the basis of this success is a high-quality education system, which every year graduates
thousands of well-prepared professionals in areas such as medicine, nursing, therapy and
rehabilitation, diagnostic and therapeutic technologies, biomedical sciences and pharmaceutical
sciences, to mention a few. More than 600 of these new graduations each year correspond to
new doctorates in the areas of life, medical and health sciences, and medical engineering.
Portugal also has a high-quality healthcare system, with excellent professionals and modernly
equipped. This quality is regularly assessed by an independent national regulatory organisation,
and there is a growing number of hospitals achieving international accreditation. And the ultimate
evidence of the quality of the Portuguese healthcare system consists on the country’s high-
standard health indicators – Portugal has one of the lowest infant mortality rates in the world,
and is in the front group of countries with the highest life expectancy at birth.
Besides its quality, which comes side-by-side with safety and innovation, the Portuguese offer in
healthcare is also cost-competitive in several market segments. If taken together with factors such
as the country’s geographic location, its climate, its tourism, culture and leisure offer, and the
hospitality of the people, for example, these characteristics make Portugal a perfect destination
for medical tourism. This reality comprises both a public and a private component that
complement and articulate with each other, thereby making available a highly qualified and
differentiated offer.
2. 2/8HCP | January 2019 | www.healthportugal.com
Given the quality of Portuguese R&D institutions and hospitals, including the expertise of its human
resources and the high-end facilities, the country is very well positioned to be a competitive
supplier of specialised scientific/technological/analytical services, as well as an attractive
destination for conducting clinical trials. The number of clinical trial applications submitted to
the national competent authority has increased by 56% between 2011 and 2017.
As a result of the quality of the Portuguese health value chain, together with the attractiveness of
the investment climate in the country, well-known multinational companies have chosen
Portugal to establish production units and/or R&D centres.
Selected indicators of the Health sector in Portugal
Indicator
(Unit)
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Source
Turnover
(thousand
million €)
- 26.5 28.1 28.7 26.2 25.4 25.1 25.9 27.0 - -
Exports of
goods
(million €)
- 627 704 702 939 1,011 1,045 1,168 1,215 1,417 1,398
R&D
investment
(million €)
165 291 365 409 365 340 325 377 400 401 462
R&D
investment -
Companies
(million €)
59 100 88 103 116 114 112 120 109 108 136
Workers in
R&D activities
(FTE)
2,987 5,574 5,625 5,348 5,894 5,690 5,194 5,230 5,589 6,063 -
Researchers
(FTE) 2,575 5,063 4,841 4,787 5,562 5,268 4,369 4,421 4,755 5,093 -
Publications
(no.) 3,605 4,284 5,054 5,790 6,120 6,889 7,774 7,989 8,096 - -
PhD
graduations
(no.)
333 361 351 415 450 534 610 - - - -
Patent
applications:
European +
PCT
(no.)
15 11 17 18 21 21 39 - - - -
Clinical trials
authorisation
applications
(no.)
136 146 116 107 88 118 114 127 137 142 137
Life
expectancy
at birth
(years)
78.7 78.9 79.3 79.6 79.8 80.0 80.2 80.4 80.6 - -
Infant
mortality rate
(‰)
3.4 3.3 3.6 2.5 3.1 3.4 2.9 2.9 2.9 3.2 2.6
Source: HCP’s Tableau de Bord (http://healthportugal.com/about-us/tableau-de-bord).
3. 3/8HCP | January 2019 | www.healthportugal.com
Health Cluster Portugal (HCP)
The Health Cluster Portugal (HCP) (www.healthportugal.com) is a private non-profit association,
founded in 2008, that currently brings together over 170 members, including R&D institutions,
universities, hospitals, organisations from civil society, and companies in the areas of
pharmaceuticals, biotechnology, medical technologies, and services. Together, HCP and its
members develop innovative projects in areas such as translational and clinical research, active
and healthy ageing, health tourism, and eHealth, with the purpose of turning knowledge into new
solutions that contribute to the improvement of human health and wellbeing, and work to make
Portugal the right place to invest and build partnerships in Health.
To learn more about HCP members, please visit www.healthportugal-directory.com
4. 4/8HCP | January 2019 | www.healthportugal.com
Mission
HCP assumes as its mission to strengthen the competitiveness of Portugal in the research, design,
development, manufacturing and commercialization of health-related products and services, in
selected market and technological niches, targeting the most demanding and relevant international
markets, based on the recognition of its excellence, technological level and competences in the
field of innovation.
Strategic Vision 2020
HCP’s Subclusters
Under a logic of smart specialisation, HCP has an ongoing process of implementing the so-called
Subclusters, which are defined as groups of institutions, based in Portugal, with capacities – at
the scientific, clinical, industrial and commercial levels – oriented towards a specific “market” within
the Health area, and organized in order to create and exploit synergies between them. At the
present time, initiatives are under way in the areas of Cancer, Neurosciences, Ophthalmology,
and Medical Tourism.
Science, Technology
& Innovation
. diseases
. pharmaceutical & biotechnology
. medical technologies
. nanotechnologies
. clinical and translational research
Business dynamics
. healthcare
. pharmaceutical & biotechnology
. medical devices
. auxiliary diagnostic means
. eHealth
People
. qualified human resources
. scientific societies
. patient associations
Public support / New agendas
. smart specialisation
. reindustrialisation
. Portugal 2020 + Horizon 2020
. incentives to investment,innovation & employment
. attraction of foreign investment
+ social and economic development
+ turnover
+ exports
+ employment (qualified)
+ health
STRATEGIC OPTIONS
well-being / active ageing
preventive, personalised and participative medicine
(diseases – neurodegenerative, cancer,
cardiovascular, degenerative osteoarticular,
inflammatory, infectious, metabolic)
health tourism
eHealth
5. 5/8HCP | January 2019 | www.healthportugal.com
HCP Membership Directory
The HCP Membership Directory, which is available at www.healthportugal-directory.com, is a
guide of organisations operating in the Portuguese health value chain, including universities, R&D
institutions, hospitals and companies in the areas of pharmaceuticals, biotechnology, medical
devices, ICT and services. Visitors can use it to access to information about HCP members and
find scientific, clinical, technological, industrial or commercial partners.
SciPort | Health in Portugal: Science and Technology Resources Database
SciPort is an open-access, user-friendly database, managed by HCP and available at
www.scienceportugal.com, that includes information about Portuguese Institutions, R&D Projects
and Service Centres in the domain of Health. Thereby, global stakeholders – for example,
researchers and companies from all over the world – are offered a “one-stop-shop” where they can
freely and easily search for scientific/technological and business partners in Portugal.
HCP@LinkedIn
HCP maintains a dynamic presence on LinkedIn, and the networking group “Health Cluster
Portugal” () is a privileged meeting point for 2,000 agents of the Health sector. Its subgroups
“HCP: I&D em Saúde | Health R&D” (), “HCP: Valorização do Conhecimento | Knowledge
Valorization” (), and “HCP: Potencial Humano | Human Potential” () are also integrated by
several hundred participants that rely on them for accessing the latest information and insights on
the Health sector – e.g., news, events, studies and reports, funding opportunities, partner searches,
technology offers, job opportunities, and training courses.
6. 6/8HCP | January 2019 | www.healthportugal.com
TRIS-HCP
The Translational and Clinical Research Infrastructures Specialisation Platform – Health
Cluster Portugal (TRIS-HCP) (http://healthportugal.com/tris-hcp) is a virtual organisational system
within HCP that brings together many of the most prominent Portuguese R&D institutions, hospitals
and academic medical centres, and their respective facilities, resources, services and expertise in
the areas of translational and clinical research, making them more accessible to other (national or
foreign) researchers and companies. TRIS-HCP is integrated in the Portuguese Roadmap of
Research Infrastructures 2014-2020 (), established by the Portuguese Foundation for Science
and Technology (FCT).
TRIS-HCP can assist (external) researchers and companies in finding the right partners for their
R&D projects, since it brings together, through its members (view list of members at
http://healthportugal.com/tris-hcp/members-mission), a wide range of resources and expertise,
mainly in the following specialisation areas:
i) Diseases – cancer, cardiovascular, infectious, metabolic, neurological, rare.
ii) Products – advanced therapy medicinal products and biologics, biomarkers, imaging and tracing,
small molecules, vaccines.
7. 7/8HCP | January 2019 | www.healthportugal.com
Project AAL4ALL – Ambient Assisted Living for All
The project AAL4ALL (www.aal4all.org) aimed at the development of an ecosystem of products
and services for Ambient Assisted Living (AAL) associated to a business model and validated
through large scale trial.
Project Do IT – Development and Operation of Translational Research
The project Do IT (http://doit.com.pt/) aimed at the creation within the Portuguese health value
chain of a series of “translational research ecosystems”, based on strong and functional
partnerships between companies, R&D centres, universities and hospitals, in order to foster an
effective transfer, valorisation and exploitation of results generated by R&D activities, including the
development of innovative and competitive products and services for the global health market.
Project HealthGainPT
The project HealthGainPT aims at developing a national multimodal digital platform for data
recording of well characterized individuals, representative of the Portuguese population, for
retrospective and prospective studies/research.
CO-PROMOTERS&PARTNERS
OBSERVERS
8. 8/8HCP | January 2019 | www.healthportugal.com
Project MedTech-2-Market – MedTech made in Portugal
The project MedTech-2-Market aims at: i) development of medical technologies and eHealth
products/services – wearables, apps, serious games, CAD-as-a-service, POC analysis, technical
furniture and bedding, packaging and dispensing; ii) development and implementation of patient
monitoring and management systems in hospital and non-hospital environments; iii) creation of a
national interoperable platform; iv) definition and implementation of testbeds in Portugal; v)
definition of systems/models for procurement and assessment of health technologies; vi) actions
for raising the awareness and increasing the acceptance about eHealth amongst users, healthcare
units and health tourism providers; vii) internationalization actions.
Regular initiatives
HCP regularly promotes initiatives in order to inform, to raise the awareness, and to promote the
discussion around themes relevant to the Health sector, as well as actions of networking and
promotion of its members and the Portuguese Health sector. Information about HCP’s past
initiatives, which have been attended by over 7,500 participants, is available at
http://healthportugal.com/about-us/regular-initiatives.
For more information about HCP, its projects and its activities, please visit www.healthportugal.com
and HCP’s LinkedIn® profile at www.linkedin.com/company/health-cluster-portugal.
OBSERVERS
MENTORS
CO-PROMOTERS&PARTNERS